化瘀散结方辅助化疗治疗痰瘀互结型非小细胞肺癌的临床研究  

Clinical efficacy of Huayu Sanjie Formula adjuvant chemoradiotherapy for lung cancer of phlegm-blood stasis type

作　　者：罗璟[1] 马腾媛 张春超 彭艳[1] LUO Jing;MA Tengyuan;ZHANG Chunchao;PENG Yan(Department of Oncology,Chuzhou Hospital of Integrated Traditional Chinese and Western Medicine,Chuzhou,Anhui 239000;Department of Respiratory Medicine,Chuzhou Hospital of Integrated Traditional Chinese and Western Medicine,Chuzhou,Anhui 239000;Department of General Surgery,Chuzhou Hospital of Integrated Traditional Chinese and Western Medicine,Chuzhou,Anhui 239000)

机构地区：[1]安徽省滁州市中西医结合医院肿瘤科,安徽滁州239000 [2]安徽省滁州市中西医结合医院呼吸科,安徽滁州239000 [3]安徽省滁州市中西医结合医院普外科,安徽滁州239000

出　　处：《河北中医》2023年第1期82-85,共4页Hebei Journal of Traditional Chinese Medicine

摘　　要：目的观察化瘀散结方辅助化疗治疗痰瘀互结型非小细胞肺癌的临床疗效。方法将61例痰瘀互结型非小细胞肺癌患者按照随机数字表法分为2组,对照组31例予单纯化疗治疗,治疗组30例在对照组基础上联合中药化瘀散结方治疗。2组均治疗6周后统计疗效,比较2组治疗前后中医症状咳嗽、咯痰、胸部闷痛或刺痛、气急、乏力、脘腹痞闷、少食、口唇紫暗、痰血评分变化情况,比较2组治疗前后肿瘤标志物血清癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA21-1)水平变化情况,比较2组治疗期间不良反应发生情况。结果治疗组控制率80.00%(24/30),对照组控制率54.84%(17/31),治疗组控制率高于对照组(P<0.05)。与本组治疗前比较,2组治疗后中医症状咳嗽、咯痰、胸部闷痛或刺痛、气急、乏力、脘腹痞闷、少食、口唇紫暗、痰血评分及总分均降低(P<0.05),且治疗组治疗后中医症状各项评分及总分均低于对照组(P<0.05)。与本组治疗前比较,2组治疗后肿瘤标志物CEA、NSE、CYFRA21-1水平均降低(P<0.05),且治疗组治疗后CEA、NSE、CYFRA21-1水平均低于对照组(P<0.05)。治疗组恶心呕吐、白细胞减少、中性粒细胞减少不良发生率均低于对照组(P<0.05)。结论化瘀散结方辅助化疗治疗痰瘀互结型非小细胞肺癌临床疗效确切,可有效改善患者中医症状,降低肿瘤标志物水平,减少药物不良反应,具有明显的减毒增效作用。Objective To observe the clinical efficacy of Huayu Sanjie Formula adjuvant chemoradiotherapy for lung cancer(LC)of phlegm-blood stasis type.Methods Totally 61 LC patients(phlegm-blood stasis type)were randomly assigned to receive either simple chemotherapy(the control group,n=31)or chemotherapy+Huayu Sanjie Formula(the treatment group,n=30).Treated for 6 weeks,the aim was to compare traditional Chinese medicine(TCM)symptom(cough,expectoration,chest pain or tingling,breathlessness,fatigue,abdominal distension,anorexia,dark purple lips,phlegm and blood)score,tumor markers(serum carcinoembryonic antigen[CEA],neuron-specific enolase[NSE],cytokeratin 19 fragment[CYFRA21-1]).The curative effect and adverse reactions were assessed.Results The disease control rate(DCR)was 80.00%(24/30)in the treatment group,higher than that of 54.84(17/31)in the control group(P<0.05).After treatment,TCM symptom scores in groups were decreased(P<0.05),which were decreased in the treatment group compared with the control group(P<0.05).CEA,NSE,CYFRA21-1 in groups were decreased(P<0.05),which were decreased in the treatment group relevant to the control group(P<0.05).The incidence of adverse reactions(nausea and vomiting,leukopenia,neutropenia)was lower in the treatment group than in the control group(P<0.05).Conclusion For LC patients(phlegm-blood stasis type),Huayu Sanjie Formula adjuvant chemoradiotherapy has definite clinical curative effect,can effectively improve TCM symptoms,decrease the levels of tumor markers,reduce adverse drug reactions,and with obvious toxicity-reducing and action-enhancing effects.

关 键 词：肺肿瘤 放化疗 辅助 中西医结合疗法 

分 类 号：R734.2[医药卫生—肿瘤]